Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.74 |
| ▸ | LAP3 | P28838 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.60 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | EPOR | P19235 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058710 | 1.00 | LTA4H (0.74) | LTA4HLAP3PPARGLNPEPMAOB | |
| SCHEMBL6162332 | 1.00 | LTA4H (0.74) | LTA4HLAP3PPARGLNPEPMAOB | |
| Hydrochloric Acid SCHEMBL3497991 | 0.99 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB | |
| Hydrochloric Acid SCHEMBL3499496 | 0.99 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB | |
| Hydrochloric Acid SCHEMBL3497988 | 0.99 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB | |
| Phenylalanine Methyl Ester SCHEMBL28633098 | 0.96 | LTA4H (0.70) | LTA4HLAP3PPARGLNPEPPPARA | |
| Butylamine SCHEMBL8391542 | 0.91 | LTA4H (0.63) | LTA4HLAP3PPARGLNPEPEPOR | |
| SCHEMBL16607620 | 0.90 | LTA4H (0.67) | LTA4HLAP3PPARGLNPEPMAOB | |
| SCHEMBL6561218 | 0.89 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB | |
| SCHEMBL1855604 | 0.89 | LTA4H (0.73) | LTA4HLAP3PPARGLNPEPMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20190256849-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| US-10294474-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9988492-B2 | Methods for post-fabrication functionalization of poly(ester ureas) | THE UNIVERSITY OF AKRON (US) | 2018-06-05 | — | — | US | disclosed |
| WO-2018044350-A1 | TARGETING LIGANDS | ARROWHEAD PHARMACEUTICALS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| US-5936089-A | PIPERIDINE DERIVATIVES; BONE DISORDERS; OBESITY; AGING; CACHEXIA ASSOCIATED WITH AIDS AND CANCER | PFIZER INC (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | LTA4H 1788/4885LAP3 3450/4885PPARG 189/4885 |
| US-20220033817-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | LTA4H 3621/4885LAP3 1609/4885PPARG 1743/4885 |
| US-20180064819-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | LTA4H 3621/4885LAP3 1609/4885PPARG 1743/4885 |
| US-10294474-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | LTA4H 3621/4885LAP3 1609/4885PPARG 1743/4885 |
| US-20190256849-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | LTA4H 3621/4885LAP3 1609/4885PPARG 1743/4885 |
| US-11174481-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | LTA4H 3621/4885LAP3 1609/4885PPARG 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.